Disease-modifying therapies (DMTs) are a group of treatments specifically designed to alter the course of Multiple Sclerosis by targeting the immune system. Unlike medications used to treat individual symptoms like pain or fatigue, DMTs work to reduce the frequency and severity of relapses, prevent the formation of new brain and spinal cord lesions, and slow the accumulation of physical disability. In 2026, the clinical standard has shifted toward the early use of high-efficacy DMTs to protect long-term brain volume and neurological function. While they are not a cure, these therapies have transformed MS from a rapidly disabling condition into a manageable chronic illness for many people.
What we will discuss in this article
- The primary clinical goals of Disease-Modifying Therapies
- How different classes of DMTs interact with the immune system
- Categorizing treatments by efficacy: Moderate vs. High
- Administration routes: Injectables, Orals, and Infusions
- The 2026 research frontier: BTK inhibitors and CNS-penetrant drugs
- Monitoring safety and the concept of NEDA (No Evidence of Disease Activity)
- Emergency guidance for severe treatment-related reactions
How DMTs work: The clinical mechanism
DMTs function by “modifying” the behaviour of the immune system to prevent it from attacking the myelin sheath.
In Multiple Sclerosis, white blood cells (lymphocytes) mistakenly cross the blood-brain barrier and attack the central nervous system. DMTs interfere with this process through several biological mechanisms:
- Immune Cell Sequestration: Some drugs trap immune cells in the lymph nodes, preventing them from entering the brain.
- Cell Depletion: Certain therapies identify and remove the specific B-cells or T-cells that are responsible for the damage.
- Immune Modulation: Other treatments change the “tone” of the immune system from pro-inflammatory to anti-inflammatory, reducing the overall level of aggression toward the nerves.
Classes of DMTs by administration
In 2026, patients and clinicians can choose from a wide range of delivery methods based on lifestyle and disease activity.
Self-Injectable Therapies
These are often used as first-line treatments for milder cases or when a well-established safety profile is prioritised. They include Beta-interferons and Glatiramer acetate. While they are generally considered moderately effective, they remain a staple for many patients due to their long-term safety data.
Oral Medications
Oral DMTs offer significant convenience and range from moderate to high efficacy.
- S1P Modulators: These prevent lymphocytes from leaving lymph nodes.
- Fumarates: These reduce inflammation and may provide neuroprotective effects.
- Cladribine: A high-efficacy treatment taken in two short courses, one year apart, that provides long-term immune “resetting.”
Intravenous Infusions
Infusions are typically the most potent DMTs and are administered in a hospital or clinic setting. High-efficacy options like Ocrelizumab (Ocrevus) and Natalizumab (Tysabri) are standard for highly active relapsing MS. In 2026, the use of subcutaneous (under the skin) versions of these infusions has increased patient convenience significantly.
The 2026 Frontier: BTK Inhibitors
The most significant development in 2026 is the advancement of Bruton Tyrosine Kinase (BTK) inhibitors into late-stage clinical use.
Unlike many older DMTs that primarily work in the bloodstream, BTK inhibitors like fenebrutinib and tolebrutinib are designed to cross the blood-brain barrier. This allows them to target the “smouldering” inflammation directly inside the central nervous system, which is believed to be the main driver of progressive disability. These drugs offer a new pathway for treating primary and secondary progressive forms of MS where traditional peripheral immune-targeting drugs have often been less effective.
Aiming for NEDA (No Evidence of Disease Activity)
The success of a DMT is measured by the clinical goal of NEDA, which is the gold standard for MS care in 2026.
[Image showing a clear MRI scan and a stable disability scale score as markers of NEDA]
A treatment is considered successful if it achieves the following three criteria:
- No Relapses: The patient experiences no new clinical attacks.
- No MRI Activity: No new or enlarging lesions appear on annual scans.
- No Disability Progression: There is no measurable worsening in physical or cognitive tests.
If NEDA is not achieved, clinicians in 2026 are increasingly proactive about “switching up” to a higher-efficacy therapy sooner rather than later to prevent the accumulation of “silent” damage.
Emergency guidance
While DMTs are life-changing, they affect the immune system and require careful clinical monitoring for rare but serious side effects.
Seek immediate medical assessment if you experience signs of a severe allergic reaction (anaphylaxis) during or after a treatment, such as swelling of the throat, difficulty breathing, or a rapid heart rate.
Seek urgent medical advice if you notice:
- A sudden, severe headache combined with confusion or personality changes (which can indicate rare brain infections like PML)
- Signs of a severe systemic infection, such as high fever, shivering, and extreme lethargy
- Yellowing of the eyes or skin (jaundice) which may indicate liver stress
- New and persistent suicidal thoughts or severe depressive episodes
- Widespread skin blistering or a rapidly spreading rash
To summarise
Disease-modifying therapies are the most powerful tools we have to manage Multiple Sclerosis by directly influencing the immune system’s behaviour. From traditional injectables to modern high-efficacy infusions and the emerging class of CNS-penetrant BTK inhibitors, the options in 2026 are more personalised than ever. By targeting the disease early and aiming for a state of No Evidence of Disease Activity, clinicians can help patients preserve their independence and neurological health for decades. Regular monitoring and a strong partnership with your neurology team are the keys to finding the right DMT for your specific journey.
Will a DMT make my current symptoms go away?
DMTs are designed to prevent future damage rather than repair old scars. While some people feel better as inflammation subsides, the primary goal is prevention.
Can I stop my DMT if I haven’t had a relapse in years?
In 2026, clinicians generally advise against stopping DMTs unless there is a specific medical reason (like age or side effects), as stopping can lead to a “rebound” of disease activity.
Are DMTs safe during pregnancy?
Some DMTs are safe, while others must be stopped months before conception. In 2026, there are specific protocols for managing MS during pregnancy to protect both the mother and the baby.
What is the difference between a DMT and a DMD?
There is no difference; Disease-Modifying Therapy (DMT) and Disease-Modifying Drug (DMD) are two terms for the same group of treatments.
Why did my doctor start me on a high-efficacy drug first?
The modern “Top-Down” approach suggests that starting with the most effective treatment immediately provides the best chance of preventing long-term disability.
Do all DMTs cause hair loss or nausea?
No. Side effects vary widely between drug classes. Many modern DMTs have very few daily side effects, though they all require blood monitoring for safety.
Can a DMT treat progressive MS?
Yes. Several DMTs are now specifically licensed for primary progressive and active secondary progressive MS, with more options currently in late-stage research.
Authority Snapshot
This article was reviewed by Dr. Stefan Petrov, a UK-trained physician with an MBBS and extensive experience in general medicine, intensive care, and emergency medicine. Dr. Petrov has contributed significantly to patient-focused medical education and is dedicated to providing evidence-based insights into the latest chronic disease treatments. He is passionate about helping patients navigate the complexities of modern neurological therapies with clarity and confidence.
